SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: paul goldstein who wrote (4060)1/13/1999 12:19:00 PM
From: paul goldstein  Read Replies (1) | Respond to of 4342
 
if three of the samples were more active then paclitaxel..that means we passed the milestone for consideration as an effective product.
paclitaxel is the "marker" in this area.
do know they are doing more research adn so forth..
but, i really would have expected some reaction from the medical field.
next event will be southern institute results i assume


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News